Fbxw12 Activators
Fbxw7 Activators are a diverse set of chemical compounds that indirectly promote the functional activity of Fbxw7 through modulation of phosphorylation and ubiquitination pathways. Cyclosporin A, by inhibiting calcineurin, halts the dephosphorylation of specific proteins, which could be potential substrates for Fbxw7, thus indirectly increasing the pool of proteins targeted by Fbxw7 for degradation. Similarly, the mTORC1 inhibitor Rapamycin, and CDK inhibitors Roscovitine and PD0332991,lead to enhanced stabilization and accumulation of phosphorylated proteins that can be recognized by Fbxw7 for ubiquitination, thereby amplifying its role in protein turnover. Proteasome inhibitors such as Bortezomib and MG132 contribute to this process by preventing the degradation of ubiquitinated proteins, increasing the substrate availability for Fbxw7-mediated degradation, and consequently enhancing the protein's functional activity. Lithium chloride and SB216763, both GSK-3 inhibitors, promote the accumulation of Fbxw7 substrates by inhibiting their GSK-3 mediated degradation, leading to a potential increase in Fbxw7-dependent ubiquitination.
Moreover, compounds like LY294002, a PI3K inhibitor, and U0126, a MEK inhibitor, indirectly facilitate Fbxw7 activity by altering the phosphorylation state of proteins within their respective pathways, which may include Fbxw7 substrates. The JNK inhibitor SP600125 also contributes to this effect by modifying the phosphorylation status of cell cycle regulatory proteins, thereby enhancing the recognition and degradation of these proteins by Fbxw7. Lastly, Trichostatin A, through its role as a histone deacetylase inhibitor, can lead to changes in gene expression that alter the cellular context and indirectly increase Fbxw7's activity by influencing the levels of proteins that Fbxw7 targets for ubiquitination. Collectively, these Fbxw7 Activators work through a variety of mechanisms to enhance the biological processes that Fbxw7 regulates, primarily by increasing the quantity or stability of its phosphorylated substrates, which are crucial for its role in protein ubiquitination and degradation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTORC1, leading to reduced protein synthesis and cell growth. This inhibition can lead to an accumulation of certain proteins that are normally targeted for degradation by Fbxw7, indirectly enhancing Fbxw7's functional activity in protein turnover. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases (CDKs). By inhibiting CDKs, roscovitine can lead to increased levels of phosphorylated proteins, some of which may be substrates for Fbxw7, thereby potentially enhancing Fbxw7's role in protein degradation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD0332991 is a selective inhibitor of CDK4/6, leading to cell cycle arrest. This inhibition may result in an accumulation of phosphorylated proteins that are substrates for Fbxw7, thus enhancing the ubiquitination and degradation processes mediated by Fbxw7. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of proteins, including those ubiquitinated by Fbxw7. This can indirectly enhance Fbxw7's role in signaling pathways by increasing the substrate availability for Fbxw7-mediated ubiquitination. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is another proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially leading to increased levels of Fbxw7 substrates and amplifying Fbxw7's role in protein ubiquitination and turnover. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3), which can result in the accumulation of phosphorylated substrates for Fbxw7, thereby enhancing Fbxw7's activity in targeting these proteins for degradation. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 is a GSK-3 inhibitor that may lead to increased levels of Fbxw7 substrates by preventing their phosphorylation-dependent degradation, indirectly enhancing the activity of Fbxw7 in protein turnover. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate the AKT pathway. Inhibition of this pathway may enhance the degradation of certain proteins by Fbxw7, as some AKT substrates overlap with those of Fbxw7. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of ERK. Inhibition of this pathway can lead to an altered phosphorylation state of proteins that could be recognized and targeted by Fbxw7 for degradation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can affect the phosphorylation status of proteins involved in cell cycle regulation. This may enhance Fbxw7's role in targeting these proteins for ubiquitination and subsequent degradation. | ||||||